Skip to main content

Triferic FDA Approval History

Last updated by Judith Stewart, BPharm on Jan 28, 2021.

FDA Approved: Yes (First approved January 23, 2015)
Brand name: Triferic
Generic name: ferric pyrophosphate citrate
Company: Rockwell Medical, Inc.
Treatment for: Anemia Associated with Chronic Renal Failure

Triferic (ferric pyrophosphate citrate) is an iron-replacement drug for treating iron deficiency in chronic kidney disease patients receiving hemodialysis.

Development timeline for Triferic

Mar 27, 2020Approval FDA Approves Triferic AVNU (ferric pyrophosphate citrate), Intravenous Formulation of Triferic for Replacement of Iron and Maintenance of Hemoglobin in Hemodialysis Patients
Jan 26, 2015Approval FDA Approves Triferic for Iron Replacement and Maintenance of Hemoglobin in Hemodialysis Patients
May 28, 2014Rockwell Medical Announces FDA Acceptance for Filing of Triferic New Drug Application
Mar 24, 2014Rockwell Medical Submits NDA for Triferic

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.